FDA approves Sun Pharma’s CEQUA for treatment of dry eye disease
CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye). CEQUA provides the highest FDA-approved concentration of cyclosporine A (CsA) and is the first
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.